We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

11 hedge funds and large institutions have $171K invested in ABVC BioPharma in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

38% more funds holding

Funds holding: 8 → 11 (+3)

0.58% less ownership

Funds ownership: 2.41% → 1.83% (-0.58%)

49% less capital invested

Capital invested by funds: $333K → $171K (-$162K)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APP
Avantax Planning Partners
Iowa
+$40K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$34.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$25.9K
4
Northern Trust
Northern Trust
Illinois
+$19.6K
5
XT
XTX Topco
Cayman Islands
+$19.5K

Top Sellers

Rank Fund Capital Flow
1
CIC
Chase Investment Counsel
Virginia
-$233K
2
Bank of America
Bank of America
North Carolina
-$4.3K
3
Wells Fargo
Wells Fargo
California
-$63

ABVC Hedge Fund Activity: Q2 2024 in Review

11 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2024, worth a combined $171K — down 49% from $333K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ABVC positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $40K. The largest seller was Chase Investment Counsel, exiting entirely with an estimated $233K sold.

  • 11 institutional investors held ABVC BioPharma (ABVC) as of Q2 2024, up from 8 in Q1 2024.
  • Funds reported $171K of ABVC BioPharma stock for Q2 2024, down 49% quarter-over-quarter.
  • 5 funds opened new ABVC BioPharma positions in Q2 2024 and 2 closed out, a net change of +3 holders.
  • The largest ABVC BioPharma buyer in Q2 2024 was Avantax Planning Partners, an estimated $40K added.
  • The largest ABVC BioPharma seller in Q2 2024 was Chase Investment Counsel, an estimated $233K sold.

Based on aggregated 13F filings for Q2 2024.